

# Axial Spondyloarthritis (axSpA) - Pipeline Insight - 2020

<https://marketpublishers.com/r/A90BCAE23A56EN.html>

Date: November 2020

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: A90BCAE23A56EN

## Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Axial Spondyloarthritis – Pipeline Insight, 2020," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial Spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Axial Spondyloarthritis Understanding

#### Axial Spondyloarthritis: Overview

Axial Spondyloarthritis (Axial SpA) is a chronic, immune-mediated inflammatory condition characterised by inflammation of the sacroiliac joints (sacroiliitis), inflammation of the spine or both resulting in chronic back pain, fatigue and significantly reduced function and quality of life. It is an umbrella term for the types of inflammatory arthritis that primarily affect the spine and the sacroiliac (SI) joints that connect the lower spine to the pelvis. Axial SpA may be categorized as either radiographic axial spondyloarthritis (r-axSpA) (also known as Ankylosing Spondylitis (AS)) and non-radiographic axial spondyloarthritis (nr-axSpA) depending on the presence of

radiographic sacroiliitis.

## Symptoms

The primary symptom of Axial Spondyloarthritis (Axial SpA) is back pain that occurs because of chronic inflammation in the joints of spine. Other symptoms of Axial Spondyloarthritis include:

nocturnal waking caused by pain

morning stiffness

fatigue and functional disability

Inflammation of the eye (uveitis)

Psoriasis

Inflammatory bowel disease

Enthesitis

## Diagnosis

Axial SpA is often mis-diagnosed or not diagnosed for several years after a patient first experiences symptoms. Early diagnosis is essential for optimal patient care. A diagnosis of Axial Spondyloarthritis is done through a combination of patient history, physical examination, and blood tests (both for HLA-B27 and for markers of inflammation, such as C-reactive protein), and imaging tests, such as X-ray and MRI.

## Treatment

Treatment for Axial Spondyloarthritis includes, NSAIDs, Biologics that are either tumor necrosis factor (TNF) inhibitor or an anti-IL-17 agent, Sulfasalazine, Analgesics, and Glucocorticoids (corticosteroids). Some of the approved biologics and their biosimilars are adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade) and secukinumab (Cosentyx). Physiotherapy as a treatment for axial SpA aims to maintain or improve function.

## Axial Spondyloarthritis Emerging Drugs Chapters

This segment of the Axial Spondyloarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### Axial Spondyloarthritis Emerging Drugs

#### Namilumab: Izana Bioscience Ltd.

Namilumab is a human monoclonal antibody targeting granulocyte macrophage-colony stimulating factor (GM-CSF). It is under Phase 2 development for the treatment of Axial Spondyloarthritis. Takeda has granted Izana a licence to develop, manufacture and commercialise Namilumab worldwide and for any indication, further to its right to sublicense under its licence agreement with Amgen.

#### Bimekizumab: UCB

Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes. Selective inhibition of IL-17F in addition to IL-17A suppresses inflammation to a greater extent. Bimekizumab is under Phase 3 development for the treatment of Axial Spondyloarthritis.

Further product details are provided in the report

### Axial Spondyloarthritis: Therapeutic Assessment

This segment of the report provides insights about the different Axial Spondyloarthritis drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Axial Spondyloarthritis

There are approx. 30+ key companies which are developing the therapies for Axial Spondyloarthritis. The companies which have their Axial Spondyloarthritis drug candidates in the most advanced stage, i.e. phase III include, UCB.

## Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Axial Spondyloarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

#### Axial Spondyloarthritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Axial Spondyloarthritis therapeutic drugs key players involved in developing key drugs.

#### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Axial Spondyloarthritis drugs.

#### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Axial Spondyloarthritis R&D. The therapies under development are focused on novel approaches to treat/improve Axial Spondyloarthritis.

#### Axial Spondyloarthritis Report Insights

Axial Spondyloarthritis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Axial Spondyloarthritis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Axial Spondyloarthritis drugs?

How many Axial Spondyloarthritis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Axial Spondyloarthritis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Axial Spondyloarthritis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Axial Spondyloarthritis and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Izana Bioscience

Kyowa Kirin Co. Ltd.

Luye Pharma Group

UCB

Galapagos

Gilead Sciences

Almirall

Sun Pharmaceutical Industries

AbbVie

Pfizer

Akeso Biopharma

Nimbus Therapeutics

Eisai Inc.

Roivant Sciences

Jiangsu Hengrui Medicine Co.

## Key Products

Namilumab

KHK4827

Secukinumab biosimilar

Bimekizumab

Filgotinib

Upadacitinib

Tofacitinib

Tildrakizumab

AK-111

NDI 031232

Gimsilumab

QX002N Qyuns Therapeutics

SHR-0302



## Contents

Introduction

Executive Summary

Axial Spondyloarthritis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Axial Spondyloarthritis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Axial Spondyloarthritis companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Axial Spondyloarthritis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Bimekizumab - UCB

Product Description

Research and Development

Product Development Activities

Mid Stage Products (Phase II)

Comparative Analysis

Namilumab: Izana Bioscience Ltd.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

## Early Stage Products (Phase I)

- Comparative Analysis

### QX002N: Qyuns Therapeutics

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report

## Pre-clinical and Discovery Stage Products

- Comparative Analysis

### AK-111: Akeso Biopharma

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report

## Inactive Products

- Comparative Analysis

Axial Spondyloarthritis Key Companies

Axial Spondyloarthritis Key Products

Axial Spondyloarthritis- Unmet Needs

Axial Spondyloarthritis- Market Drivers and Barriers

Axial Spondyloarthritis- Future Perspectives and Conclusion

Axial Spondyloarthritis Analyst Views

Axial Spondyloarthritis Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Axial Spondyloarthritis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Axial Spondyloarthritis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Axial Spondyloarthritis (axSpA) - Pipeline Insight - 2020

Product link: <https://marketpublishers.com/r/A90BCAE23A56EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A90BCAE23A56EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970